{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+100+mg", "query": { "intervention": "Sitagliptin 100 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 88, "total_pages": 9, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sitagliptin+100+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-20T21:50:19.338Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT02365233", "title": "Fatty Liver Study in Patients With Type II Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type II Diabetes", "Nonalcoholic Fatty Liver" ], "interventions": [ { "name": "DPP4 inhibitor", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Lantus insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-05-01", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365233" }, { "nct_id": "NCT00936663", "title": "Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes", "End Stage Renal Disease" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 3, "start_date": "2009-07-06", "completion_date": "2010-06-01", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00936663" }, { "nct_id": "NCT01093651", "title": "Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Diabetes", "Insulin Resistance" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2010-06", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-02-17", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01093651" }, { "nct_id": "NCT01933672", "title": "Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "PF-04937319 once-daily", "type": "DRUG" }, { "name": "PF-04937319 split-dose", "type": "DRUG" }, { "name": "Sitagliptin once-daily", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 33, "start_date": "2013-10", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-09-27", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 8, "location_summary": "DeLand, Florida • South Miami, Florida • High Point, North Carolina + 3 more", "locations": [ { "city": "DeLand", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "South Miami", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01933672" }, { "nct_id": "NCT01829464", "title": "TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TAK-875", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2013-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 78 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01829464" }, { "nct_id": "NCT01035879", "title": "Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "MBX-2982", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2009-12", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 4, "location_summary": "Los Angeles, California • Las Vegas, Nevada • Binghamton, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Binghamton", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01035879" }, { "nct_id": "NCT00751114", "title": "Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "35 Years to 70 Years" }, "enrollment_count": 515, "start_date": "2008-11", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00751114" }, { "nct_id": "NCT01859793", "title": "Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes", "Atherosclerosis" ], "interventions": [ { "name": "sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 38, "start_date": "2013-06", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2016-10-21", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859793" }, { "nct_id": "NCT00760344", "title": "Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "SYR-472", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 386, "start_date": "2007-03", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2016-06-22", "last_synced_at": "2026-09-20T21:50:19.338Z", "location_count": 105, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00760344" } ] }